John Shaughnessy

John Shaughnessy

UNVERIFIED PROFILE

Are you John Shaughnessy?   Register this Author

Register author
John Shaughnessy

John Shaughnessy

Publications by authors named "John Shaughnessy"

Are you John Shaughnessy?   Register this Author

100Publications

1899Reads

50Profile Views

Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia.

Clin Cancer Res 2019 01 2;25(1):201-209. Epub 2018 Oct 2.

Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, Iowa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1435DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320275PMC
January 2019

Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression.

Genes Chromosomes Cancer 2015 Nov 29;54(11):692-701. Epub 2015 Jul 29.

Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22280DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644988PMC
November 2015

Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.

Am J Hematol 2013 Jun 28;88(6):463-71. Epub 2013 Mar 28.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23433DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971999PMC
June 2013

Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine.

Clin Cancer Res 2012 Nov 27;18(21):6065-73. Epub 2012 Aug 27.

Department of Data Science, The Institute of Statistical Mathematics, Tachikawa, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-1206DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3744097PMC
November 2012

Proteasome inhibitors: introduction.

Semin Hematol 2012 Jul;49(3):193-5

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2012.05.001DOI Listing
July 2012

Proteasome inhibitors and bone disease.

Semin Hematol 2012 Jul;49(3):243-8

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2012.04.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383607PMC
July 2012

Prediction of cytogenetic abnormalities with gene expression profiles.

Blood 2012 May 10;119(21):e148-50. Epub 2012 Apr 10.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2011-10-388702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3367903PMC
May 2012

Ribosomal protein metallopanstimulin-1 impairs multiple myeloma CAG cells growth and inhibits fibroblast growth factor receptor 3.

Clin Lymphoma Myeloma Leuk 2011 Dec 1;11(6):490-7. Epub 2011 Sep 1.

Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2011.06.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384726PMC
December 2011

Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile.

BMC Genomics 2011 Dec 23;12 Suppl 5:S3. Epub 2011 Dec 23.

The Center for Bioinformatics and The institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai, 200241, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2164-12-S5-S3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287499PMC
December 2011

Self-generated retrievals while multitasking improve memory for names.

Memory 2011 Nov;19(8):968-74

Department of Psychology, Augustana College, Sioux Falls, SD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09658211.2011.626426DOI Listing
November 2011

The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.

Int J Hematol 2011 Oct 15;94(4):321-333. Epub 2011 Oct 15.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, Slot 776, Little Rock, AR, 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-011-0948-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433024PMC
October 2011

Overview of biological database mapping services for interoperation between different 'omics' datasets.

Hum Genomics 2011 Oct;5(6):703-8

University of Arkansas Little Rock/University of Arkansas Medical Sciences Joint Bioinformatics Program, AR 72204, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525252PMC
October 2011

Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.

J Urol 2011 Jan 12;185(1):104-10. Epub 2010 Nov 12.

Department of Urology, University of Texas Health Science Center, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2010.08.088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020904PMC
January 2011

Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.

PLoS One 2010 Dec 20;5(12):e15233. Epub 2010 Dec 20.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0015233PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004797PMC
December 2010

The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models.

Authors:
Leming Shi Gregory Campbell Wendell D Jones Fabien Campagne Zhining Wen Stephen J Walker Zhenqiang Su Tzu-Ming Chu Federico M Goodsaid Lajos Pusztai John D Shaughnessy André Oberthuer Russell S Thomas Richard S Paules Mark Fielden Bart Barlogie Weijie Chen Pan Du Matthias Fischer Cesare Furlanello Brandon D Gallas Xijin Ge Dalila B Megherbi W Fraser Symmans May D Wang John Zhang Hans Bitter Benedikt Brors Pierre R Bushel Max Bylesjo Minjun Chen Jie Cheng Jing Cheng Jeff Chou Timothy S Davison Mauro Delorenzi Youping Deng Viswanath Devanarayan David J Dix Joaquin Dopazo Kevin C Dorff Fathi Elloumi Jianqing Fan Shicai Fan Xiaohui Fan Hong Fang Nina Gonzaludo Kenneth R Hess Huixiao Hong Jun Huan Rafael A Irizarry Richard Judson Dilafruz Juraeva Samir Lababidi Christophe G Lambert Li Li Yanen Li Zhen Li Simon M Lin Guozhen Liu Edward K Lobenhofer Jun Luo Wen Luo Matthew N McCall Yuri Nikolsky Gene A Pennello Roger G Perkins Reena Philip Vlad Popovici Nathan D Price Feng Qian Andreas Scherer Tieliu Shi Weiwei Shi Jaeyun Sung Danielle Thierry-Mieg Jean Thierry-Mieg Venkata Thodima Johan Trygg Lakshmi Vishnuvajjala Sue Jane Wang Jianping Wu Yichao Wu Qian Xie Waleed A Yousef Liang Zhang Xuegong Zhang Sheng Zhong Yiming Zhou Sheng Zhu Dhivya Arasappan Wenjun Bao Anne Bergstrom Lucas Frank Berthold Richard J Brennan Andreas Buness Jennifer G Catalano Chang Chang Rong Chen Yiyu Cheng Jian Cui Wendy Czika Francesca Demichelis Xutao Deng Damir Dosymbekov Roland Eils Yang Feng Jennifer Fostel Stephanie Fulmer-Smentek James C Fuscoe Laurent Gatto Weigong Ge Darlene R Goldstein Li Guo Donald N Halbert Jing Han Stephen C Harris Christos Hatzis Damir Herman Jianping Huang Roderick V Jensen Rui Jiang Charles D Johnson Giuseppe Jurman Yvonne Kahlert Sadik A Khuder Matthias Kohl Jianying Li Li Li Menglong Li Quan-Zhen Li Shao Li Zhiguang Li Jie Liu Ying Liu Zhichao Liu Lu Meng Manuel Madera Francisco Martinez-Murillo Ignacio Medina Joseph Meehan Kelci Miclaus Richard A Moffitt David Montaner Piali Mukherjee George J Mulligan Padraic Neville Tatiana Nikolskaya Baitang Ning Grier P Page Joel Parker R Mitchell Parry Xuejun Peng Ron L Peterson John H Phan Brian Quanz Yi Ren Samantha Riccadonna Alan H Roter Frank W Samuelson Martin M Schumacher Joseph D Shambaugh Qiang Shi Richard Shippy Shengzhu Si Aaron Smalter Christos Sotiriou Mat Soukup Frank Staedtler Guido Steiner Todd H Stokes Qinglan Sun Pei-Yi Tan Rong Tang Zivana Tezak Brett Thorn Marina Tsyganova Yaron Turpaz Silvia C Vega Roberto Visintainer Juergen von Frese Charles Wang Eric Wang Junwei Wang Wei Wang Frank Westermann James C Willey Matthew Woods Shujian Wu Nianqing Xiao Joshua Xu Lei Xu Lun Yang Xiao Zeng Jialu Zhang Li Zhang Min Zhang Chen Zhao Raj K Puri Uwe Scherf Weida Tong Russell D Wolfinger

Nat Biotechnol 2010 Aug 30;28(8):827-38. Epub 2010 Jul 30.

National Center for Toxicological Research, US Food and Drug Administration, Jefferson, Arkansas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nbt.1665DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315840PMC
August 2010

Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.

J Clin Oncol 2010 Jun 17;28(18):3023-7. Epub 2010 May 17.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.26.4465DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903335PMC
June 2010

High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.

Proc Natl Acad Sci U S A 2010 Apr 12;107(17):7904-9. Epub 2010 Apr 12.

Donna D and Donald M Lambert Laboratory for Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0908441107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2867889PMC
April 2010

Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma.

Br J Haematol 2010 Mar 24;148(5):726-38. Epub 2009 Nov 24.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2009.08009.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683858PMC
March 2010

Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.

Blood 2010 Jan 16;115(1):61-70. Epub 2009 Oct 16.

The Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2009-03-210526DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803692PMC
January 2010

TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.

Br J Haematol 2009 Nov 21;147(3):347-51. Epub 2009 Aug 21.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2009.07864.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675654PMC
November 2009

The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth.

Blood 2009 Aug 13;114(9):1803-12. Epub 2009 Jul 13.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2009-01-201954DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738568PMC
August 2009

RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma.

Blood 2009 Jul 20;114(3):600-7. Epub 2009 May 20.

The Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2008-12-194126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713470PMC
July 2009

Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.

Br J Haematol 2009 Jun 8;145(6):775-87. Epub 2009 Apr 8.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2009.07696.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748971PMC
June 2009

Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.

Blood 2009 Apr 4;113(18):4319-30. Epub 2009 Feb 4.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2008-08-174300DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676089PMC
April 2009

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

J Bone Miner Res 2009 Mar;24(3):425-36

Academic Unit of Bone Biology, Section of Musculoskeletal Sciences, University of Sheffield School of Medicine and Biomedical Sciences, Sheffield, Yorkshire, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1359/jbmr.081104DOI Listing
March 2009

Retrieval opportunities while multitasking improve name recall.

Memory 2008 Nov 27;16(8):896-909. Epub 2008 Sep 27.

Michigan State University, East Lansing, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09658210802360611DOI Listing
November 2008

First thalidomide clinical trial in multiple myeloma: a decade.

Blood 2008 Aug 23;112(4):1035-8. Epub 2008 May 23.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2008-02-140954DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515147PMC
August 2008

Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth.

Blood 2008 Jul 14;112(2):374-82. Epub 2008 Mar 14.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 77205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2007-10-120253DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442747PMC
July 2008

Cancer: An unexpected addiction.

Nature 2008 Jul;454(7201):172-3

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/454172aDOI Listing
July 2008

Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.

Bone 2008 Apr 27;42(4):669-80. Epub 2007 Dec 27.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2007.12.006DOI Listing
April 2008

Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myeloma.

Stat Med 2008 Mar;27(7):1106-20

Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/sim.2997DOI Listing
March 2008

Sample size calculations based on ranking and selection in microarray experiments.

Biometrics 2008 Mar 3;64(1):217-26. Epub 2007 Aug 3.

Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Yoshidakonoe-cho, Sakyo-ku, Kyoto 606-8501, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1541-0420.2007.00875.xDOI Listing
March 2008

Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma.

Mol Cancer Ther 2008 Mar 4;7(3):500-9. Epub 2008 Mar 4.

The Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-07-0524DOI Listing
March 2008

Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.

Blood 2008 Jan 12;111(2):806-15. Epub 2007 Oct 12.

Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, and Department of Immunology and Transfusion Medicine, St Olavs University Hospital, Trondheim, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2007-07-101139DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2200854PMC
January 2008

Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.

J Immunother 2007 Nov-Dec;30(8):847-54

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0b013e318158fcffDOI Listing
January 2008

Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.

Blood 2007 Sep 21;110(5):1587-94. Epub 2007 May 21.

Department of Lymphoma and Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2007-03-082529DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1975842PMC
September 2007

Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.

Br J Haematol 2007 Sep;138(6):802-11

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2007.06742.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748973PMC
September 2007

Smoldering multiple myeloma.

N Engl J Med 2007 Sep;357(10):1048; author reply 1049-50

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc072069DOI Listing
September 2007

CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.

Blood 2007 Jun 15;109(11):4995-5001. Epub 2007 Feb 15.

Donna D and Donald M. Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W. Markham Street, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2006-07-038703DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885527PMC
June 2007

Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.

J Biol Chem 2007 May 8;282(18):13326-33. Epub 2007 Mar 8.

Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M611259200DOI Listing
May 2007